Amgen

Yahoo Finance • 2 hours ago

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amgen Inc. (NASDAQ: AMGN) on behalf of long-term stockholders follow... Full story

Yahoo Finance • 4 days ago

POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in NEJM and Presented at AAAAI/WAO 2025 THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca tod... Full story

Yahoo Finance • 5 days ago

Amgen Inc. (AMGN) Invests $200M in AI-Focused Tech Center in India, Plans to Hire 2,000 by 2025

We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street.In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other AI stocks. In a recent discussion at CNBC's 'Squ... Full story

Yahoo Finance • 9 days ago

Medtronic’s BrainSense brain stimulation system approved by FDA for Parkinson’s

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like Parkinson’s, however, deep brain stimulation,... Full story

Yahoo Finance • 10 days ago

Is Amgen Inc. (AMGN) One of the Best Performing Dow Stocks So Far in 2025?

We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best performing Dow stocks so far in 2025. The Dow is a reno... Full story

Yahoo Finance • 23 days ago

PRIMECAP Management's Strategic Moves: A Closer Look at Eli Lilly and Co

Insights from the Fourth Quarter 2024 13F Filing PRIMECAP Management (Trades, Portfolio) recently submitted its 13F filing for the fourth quarter of 2024, offering a glimpse into its strategic investment decisions. Founded in 1983 in Pasa... Full story

Yahoo Finance • 24 days ago

3 Fabulous Dividend Stocks to Buy in February

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month. Here's why they like... Full story

Yahoo Finance • 25 days ago

68-Year-Old Earning $4,300/Month in Dividends Shares His Top 7 Stock Picks — 'Dividends Have Been Consistent, Stable'

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. U.S. markets were seeing volatility as technology earnings began to worry investors due to soft forecasts and mounting AI-related expense... Full story

Yahoo Finance • last month

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average(DJINDICES: ^DJI) had just a 12.9% return, compared to 23.3% for the S&P 500(SNPINDEX: ^GSPC) and 28.6% for the Nasdaq Composite. Eight of... Full story

Yahoo Finance • last month

Here’s Why Amgen Inc. (AMGN) Is Among the Highest Yielding Dividend Stocks In the Dow

We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow.In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other high yield dividend stocks. Dow is one of the most w... Full story

Yahoo Finance • 5 months ago

Insiders At Amgen Sold US$4.0m In Stock, Alluding To Potential Weakness

The fact that multiple Amgen Inc. (NASDAQ:AMGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When analyzing insider transactions, it is usually more valuable to kn... Full story

Yahoo Finance • 5 months ago

Amgen must face lawsuit claiming it hid $10.7 billion tax bill

NEW YORK (Reuters) - A federal judge said Amgen must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders it might owe the Internal Revenue Service $10.7 billion in taxes and penalties. U.S. Distric... Full story

Yahoo Finance • 5 months ago

Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best healthcare stocks to buy according to h... Full story

Yahoo Finance • 5 months ago

Amgen Inc. (AMGN): An Undervalued Wide Moat Stock to Buy According to Analysts

We recently compiled a list of the 10 Undervalued Wide Moat Stocks to Buy According to Analysts.In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other undervalued wide moat stocks. The US e... Full story

Yahoo Finance • 5 months ago

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab). HORIZ... Full story

Yahoo Finance • 5 months ago

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab... Full story

Yahoo Finance • 5 months ago

TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE

THOUSAND OAKS, Calif., Sept. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Ey... Full story

Yahoo Finance • 5 months ago

Amgen (NASDAQ:AMGN) shareholders have earned a 15% CAGR over the last five years

The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, while the Amgen Inc. (NASDAQ:AMGN) share price is up 73%... Full story

Yahoo Finance • 5 months ago

AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE

THOUSAND OAKS, Calif., Sept. 23, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m. PT on Tuesday, Sept. 24, 2024, to discuss new topline clinical data from the rocatinlimab (AMG 4... Full story

Yahoo Finance • 6 months ago

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types THOUSAND OAKS, Calif., Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipe... Full story